🌟 New Case Study : Alzheimer’s Disease Research! 🌟 We are excited to introduce a new case study for evaluating glutamate uptake capacity of iPSC-derived astrocytes from Alzheimer’s disease patient with APOE4 polymorphisms. Alzheimer’s disease (AD) is the most common form of dementia, affecting 50-60% of those with dementia worldwide. The APOE4 polymorphisms are the strongest genetic risk factor for the development of sporadic AD. In the central nervous system, glutamate is the main excitatory neurotransmitter, that plays a crucial role in synaptic transmission. However, excess accumulation of glutamate can trigger excitotoxicity in post-synaptic neurons, contributing to neurodegeneration in AD. To evaluate glutamate uptake capacity, we have developed astrocytes derived from iPSCs of AD patients with the APOE4 polymorphisms by measuring the concentration of glutamate in the culture supernatant. This assay system could be a valuable tool for advancing our understanding of AD pathology and supporting drug development. For more information, please contact us. 👉https://lnkd.in/engPRADr Additionally, we will be showcasing our research at the 15th conference on biomolecular screenology on November 22. Stay tuned for more updates on our findings! #Ricoh #Alzheimer’s #Alzheimer’sResearch #Alzheimer’sDisease #iPSC #APOE4 #Biotechnology #DrugDiscovery #Neuroscience
